Manejo perioperatorio de tumores cerebrales: rol del neurocirujano
Palabras clave:
tumores cerebrales, evaluación preoperatoria, neurocirugíaResumen
El manejo perioperatorio de los pacientes con tumores cerebrales es un reto para el neurocirujano y todo el equipo quirúrgico. El medico tratante debe considerar factores como el tipo de tumor, la extensión de la enfermedad, el tratamiento recibido, la presencia de comorbilidades y el pronostico mismo de la patología. La ejecución correcta de todos los aspectos implicados en el manejo perioperatorio en pacientes con tumores cerebrales contribuirán a prolongar la vida y a mejorar la calidad de vida de los pacientes.
Descargas
Citas
1. BAKAY L. Cruveilhier on meningiomas (1829-1842). Surg Neurol 1989; 32: 159-164.
https://doi.org/10.1016/0090-3019(89)90206-1
2. KIM Y-H, SONG SW, LEE JY, KIM JW, KIM YH, PHI JH et al. Surgically treated brain tumors: a retrospective case series of 10,009 cases at a single institution. World Neurosurg 2011; 76: 555-563.
https://doi.org/10.1016/j.wneu.2011.04.032
3. WRENSCH M, MINN Y, CHEW T, BONDY M, BERGER MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002; 4: 278-299.
https://doi.org/10.1093/neuonc/4.4.278
4. FERLAY J, SHIN HR, BRAY F, FORMAN D, MATHERS C, PARKIN DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
https://doi.org/10.1002/ijc.25516
5. ARORA RS, ALSTON RD, EDEN TOB, ESTLIN EJ, MORAN A, GERACI M et al. Are reported increases in incidence of primary CNS tumours real? An analysis of longitudinal trends in England, 1979-2003. Eur J Cancer 2010; 46: 1607-1616.
https://doi.org/10.1016/j.ejca.2010.02.007
6. ZADA G, BOND AE, WANG YP, GIANNOTTA SL, DEAPEN D. Incidence trends in the anatomic location of primary malignant brain tumors in the United States: 1992-2006. World Neurosurg 2012; 77: 518-524.
https://doi.org/10.1016/j.wneu.2011.05.051
7. GOURTSOYIANNIS N, ROS P. Radiologic-Pathologic Correlations from Head to Toe. Berlin/Heidelberg: Springer-Verlag; 2005.
https://doi.org/10.1007/b137876
8. PÉREZ-ORTIZ L, GALARRAGA-INZA J, GÓMEZ-SUÁREZ H, TAMAYO-SUÁREZ JD. Clasificación de los gliomas astrocíticos. Breves consideraciones. Rev Neurol 2000; 31: 1180-1183.
https://doi.org/10.33588/rn.3112.2000147
9. VERNOOIJ MW, IKRAM MA, TANGHE HL, VINCENT AJPE, HOFMAN A, KRESTIN GP et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357: 1821-1828.
https://doi.org/10.1056/NEJMoa070972
10. DEANGELIS LM. Brain tumors. N Engl J Med 2001; 344: 114-123.
https://doi.org/10.1056/NEJM200101113440207
11. RICARD D, IDBAIH A, DUCRAY F, LAHUTTE M, HOANG-XUAN K, DELATTRE JY. Primary brain tumours in adults. Lancet 2012; 379: 1984-1996.
https://doi.org/10.1016/S0140-6736(11)61346-9
12. FOKAS E, STEINBACH JP, RÖDEL C. Biology of brain metastases and novel targeted therapies: Time to translate the research. Biochim Biophys Acta 2013; 1835: 61-75.
https://doi.org/10.1016/j.bbcan.2012.10.005
13. ALBANESE C, RODRIGUEZ OC, VANMETER J, FRICKE ST, ROOD BR, LEE Y et al. Preclinical magnetic resonance imaging and systems biology in cancer research: current applications and challenges. Am J Pathol 2013; 182: 312-318.
https://doi.org/10.1016/j.ajpath.2012.09.024
14. ERDEM-ERASLAN L, GRAVENDEEL LA, DE ROOI J, EILERS PHC, IDBAIH A, SPLIET WGM et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu. J Clin Oncol 2013; 31: 328-336.
https://doi.org/10.1200/JCO.2012.44.1444
15. HELFT PR. Am I obligated to give therapy against my better judgment? Oncology (Williston Park) 2012; 26: 995-996.
16. KATO Y, NISHIHARA H, YUZAWA S, MOHRI H, KANNO H, HATANAKA Y et al. Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine. Brain Tumor Pathol 2012. Nov 20 (Epub ahead of print)
https://doi.org/10.1007/s10014-012-0124-y
17. LIN SP, LEE YT, WANG JY, MILLER SA, CHIOU SH, HUNG MC et al. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27. PloS One 2012; 7: e49605.
https://doi.org/10.1371/journal.pone.0049605
18. NEIDERT MC, SCHOOR O, TRAUTWEIN C, TRAUTWEIN N, CHRIST L, MELMS A et al. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. J Neurooncol 2013; 111: 285-294.
https://doi.org/10.1007/s11060-012-1028-8
19. BOHAN E, GLASS-MACENKA D. Surgical management of patients with primary brain tumors. Semin Oncol Nurs 2004; 20: 240-252.
https://doi.org/10.1016/S0749-2081(04)00088-9
20. BRICOLO A. Surgical management of intrinsic brain stem gliomas. Oper Tech in Neurosurg 2000; 3: 137-154.
https://doi.org/10.1053/oy.2000.6559
21. DEMAKAS JJ, SONNTAG VK, KAPLAN AM, KELLEY JJ, WAGGENER JD. Surgical management of pineal area tumors in early childhood. Surg Neurol 1982; 17: 435-440.
https://doi.org/10.1016/S0090-3019(82)80014-1
22. DRUMMOND K, OJEMANN R. Surgical principles in the management of brain tumors. Brain Tumors, Edinburgh: W.B. Saunders; 2012; 282-295.
https://doi.org/10.1016/B978-0-443-06967-3.00014-4
23. FASANO VA, URCIUOLI R, PONZIO RM, LANOTTE MM. The effects of new technologies on the surgical management of brainstem tumors. Surg Neurol 1986; 25: 219-226.
https://doi.org/10.1016/0090-3019(86)90231-4
24. FRAZIER J, JALLO G. Chapter 13 - Surgical Management of Brain Stem Tumors in Adults. Schmidek and Sweet's Operative Neurosurgical Techniques, Philadelphia: W.B. Saunders; 2012; 160-168.
https://doi.org/10.1016/B978-1-4160-6839-6.10013-9
25. JALLO G, KOTHBAUER K, EPSTEIN F. Surgical management of cervicomedullary and dorsally exophytic brain stem tumors. Operative Techniques in Neurosurgery 2000; 3: 131-136.
https://doi.org/10.1053/oy.2000.6565
26. KELLNER CP, D'AMBROSIO AL. Surgical management of brain metastases. Neurosurg Clin N Am 2011; 22: 53-59, vi.
https://doi.org/10.1016/j.nec.2010.08.003
27. LANG SS, BESLOW LA, GABEL B, JUDKINS AR, FISHER MJ, SUTTON LN et al. Surgical treatment of brain tumors in infants younger than six months of age and review of the literature. World Neurosurg 2012; 78: 137-144.
https://doi.org/10.1016/j.wneu.2011.09.012
28. PANT B, SHRESTHA P. Management of brain tumor in Nepal. Int Congr Ser 2004; 1259: 149-155.
https://doi.org/10.1016/S0531-5131(03)01405-5
29. PATEL TR, YU JB, PIEPMEIER JM. Role of neurosurgery and radiation therapy in the management of brain tumors. Hematol Oncol Clin North Am 2012; 26: 757-777.
https://doi.org/10.1016/j.hoc.2012.04.001
30. WEN PY, SCHIFF D, KESARI S, DRAPPATZ J, GIGAS DC, DOHERTY L. Medical management of patients with brain tumors. J Neurooncol 2006; 80: 313-332.
https://doi.org/10.1007/s11060-006-9193-2
31. FERSON D, DEMONTE F. Anesthetic management of patients undergoing surgery for brain tumors. Anesthesiology Clin N Am 1998; 16: 663-675.
https://doi.org/10.1016/S0889-8537(05)70049-3
32. KAAKEH Y, OVERHOLSER BR, LOPSHIRE JC, TISDALE JE. Drug-induced atrial fibrillation. Drugs 2012; 72: 1617-1630.
https://doi.org/10.2165/11633140-000000000-00000
33. KHARIN SN, KRANDYCHEVA VV, STRELKOVA MV, TSVETKOVA AS, SHMAKOV DN. Doxorubicin-induced changes of ventricular repolarization heterogeneity: results of a chronic rat study. Cardiovasc Toxicol 2012; 12: 312-317.
https://doi.org/10.1007/s12012-012-9172-0
34. RATTERREE W, GIEGER T, PARIAUT R, SAELINGER C, STRICKLAND K. Value of echocardiography and electrocardiography as screening tools prior to Doxorubicin administration. J Am Anim Hosp Assoc 2012; 48: 89-96.
https://doi.org/10.5326/JAAHA-MS-5680
35. XIN Y, ZHANG S, GU L, LIU S, GAO H, YOU Z et al. Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicin-induced cardiotoxicity in the beagle dogs. Biol Pharm Bull 2011; 34: 1523-1526.
https://doi.org/10.1248/bpb.34.1523
36. PAUN A, LEMAY AM, TOMKO TG, HASTON CK. Association analysis reveals genetic variation altering bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 2013; 48: 330-336.
https://doi.org/10.1165/rcmb.2012-0078OC
37. TRIVEDI R, REDENTE EF, THAKUR A, RICHES DWH, KOMPELLA UB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 2012; 23: 505101.
https://doi.org/10.1088/0957-4484/23/50/505101
38. BURNS WA, MCFARLAND W, MATTHEWS MJ. Busulfan-induced pulmonary disease. Report of a case and review of the literature. Am Rev Respir Dis 1970; 101: 408-413.
39. GUY C, VERGNON JM, VASSELON C, OLLAGNIER M. Fibrose pulmonaire au busulfan. Thérapie 1986; 41: 315-316.
40. MASSIN F, FUR A, REYBET-DEGAT O, CAMUS P, JEANNIN L. [Busulfan-induced pneumopathy]. Rev Mal Respir 1987; 4: 3-10.
41. CHEN H-H, CHEN T-W, LIN H. Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferator-activated receptor alpha-regulated heme oxygenase-1. Mol Pharmacol 2010; 78: 36-45.
https://doi.org/10.1124/mol.109.061101
42. DONADIO C, LUCCHESI A, ARDINI M, COSIO S, FANUCCHI A, GADDUCCI A. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer. Ther Drug Monit 2009; 31: 63-69.
https://doi.org/10.1097/FTD.0b013e3181947812
43. FUJIEDA M, MATSUNAGA A, HAYASHI A, TAUCHI H, CHAYAMA K, SEKINE T. Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children. J Toxicol Sci 2009; 34 Suppl 2: SP 251-257.
https://doi.org/10.2131/jts.34.SP251
44. KINTZEL PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24: 19-38.
https://doi.org/10.2165/00002018-200124010-00003
45. KORKMAZ A, TOPAL T, OTER S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol 2007; 23: 303-312.
https://doi.org/10.1007/s10565-006-0078-0
46. MACEDO FYB, MOURÃO LTC, FREITAS HC, LIMA RCP, WONG DVT, ORIÁ RB et al. Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis. Inflammation 2012;35:297-307.
https://doi.org/10.1007/s10753-011-9319-3
47. MOTA JM, BRITO GA, LOIOLA RT, CUNHA FQ, RIBEIRO R DE A. Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis. Int Braz J Urol 2007; 33: 704-710.
https://doi.org/10.1590/S1677-55382007000500013
48. VIEIRA MM, BRITO GAC, BELARMINO-FILHO JN, MACEDO FYBM, NERY EA, CUNHA FQ et al. Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. Int J Urol 2003; 10: 595-602.
https://doi.org/10.1046/j.1442-2042.2003.00709.x
49. AL-JAFARI AA, DUHAIMAN AS, KAMAL MA. Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology 1995; 96: 1-6.
https://doi.org/10.1016/0300-483X(94)02848-O
50. AL-JAFARI AA, SHAKIL S, REALE M, KAMAL MA. Human platelet acetylcholinesterase inhibition by cyclophosphamide: a combined experimental and computational approach. CNS Neurol Disord Drug Targets 2011; 10: 928-935.
https://doi.org/10.2174/187152711799219280
51. BODUR E. Human serum butyrylcholinesterase interactions with cisplatin and cyclophosphamide. Biochimie 2010; 92: 979-984.
https://doi.org/10.1016/j.biochi.2010.04.010
52. KAMAL MA, REALE M, AL-JAFARI AA. Multiple approaches to analyse the data for rat brain acetylcholinesterase inhibition by cyclophosphamide. Neurochem Res 2010; 35: 1501-1509.
https://doi.org/10.1007/s11064-010-0199-y
53. SHAKIL S, KAMAL MA, TABREZ S, ABUZENADAH AM, CHAUDHARY AGA, DAMANHOURI GA. Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study. CNS Neurol Disord Drug Targets 2012; 11: 142-147.
https://doi.org/10.2174/187152712800269669
54. PILGRIM CHC, THOMSON BN, BANTING S, PHILLIPS WA, MICHAEL M. The developing clinical problem of chemotherapy-induced hepatic injury. ANZ Journal of Surgery 2012; 82: 23-29.
https://doi.org/10.1111/j.1445-2197.2011.05789.x
55. CARR C, NG J, WIGMORE T. The side effects of chemotherapeutic agents. Curr Anaesth Crit Care 2008; 19: 70-79.
https://doi.org/10.1016/j.cacc.2008.01.004
56. FLOYD J, MIRZA I, SACHS B, PERRY MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33: 50-67.
https://doi.org/10.1053/j.seminoncol.2005.11.002
57. FLEISHER LA, BECKMAN JA, BROWN KA, CALKINS H, CHAIKOF EL, CHAIKOF E et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guideline. J Am Coll Cardiol 2007; 50: e159-241.
https://doi.org/10.1161/CIRCULATIONAHA.107.185699
58. FLEISHER LA, BECKMAN JA, BROWN KA, CALKINS H, CHAIKOF EL, FLEISCHMANN KE et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol 2009; 54: e13-e118.
https://doi.org/10.1016/j.jacc.2009.07.010
59. SALES LLOPIS J. Evaluación preoperatoria en Neurocirugía, Nociones de neuroanestesia, Evaluación neurofisiológica preoperatoria. Rev Neurocirugía Contemporánea 2009; 3; 186-197.
60. CAMERON MH, KLEIN EL. Screening for medical disease--nervous system disorders. J Hand Ther 2010; 23: 158-171; quiz 172.
https://doi.org/10.1016/j.jht.2009.11.003
61. TERRET C, ALBRAND G, MONCENIX G, DROZ JP. KARNOFSKY Performance Scale (KPS) or Physical Performance Test (PPT)? That is the question. Crit Rev Oncol Hematol 2011; 77: 142-147.
https://doi.org/10.1016/j.critrevonc.2010.01.015
62. IANSSEN T, LYDERSEN S, TORP S, R J. Malignant brain tumors-effect of repeated resection and adjuvant treatment. Int Congr Ser 2004; 1259: 45-52.
https://doi.org/10.1016/S0531-5131(03)01696-0
63. KARNOFSKY D, BURCHENAL J. THE CLINICAL Evaluation of Chemotherapeutic Agents in Cancer. Columbia Univ Press; 1949.
64. DOWLING C, BOLLEN AW, NOWOROLSKI SM, MCDERMOTT MW, BARBARO NM, DAY MR et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. Am J Neuroradiol 2001; 22: 604-612.
65. KAMADA K, TODO T, MASUTANI Y, AOKI S, INO K, TAKANO T et al. Combined use of tractography-integrated functional neuronavigation and direct fiber stimulation. J Neurosurg 2005; 102: 664-672.
https://doi.org/10.3171/jns.2005.102.4.0664
66. KAMADA K, TODO T, MASUTANI Y, AOKI S, INO K, MORITA A et al. Visualization of the frontotemporal language fibers by tractography combined with functional magnetic resonance imaging and magnetoencephalography. J Neurosurg 2007; 106: 90-98.
https://doi.org/10.3171/jns.2007.106.1.90
67. ARBIZU J, DOMÍNGUEZ PD, DIEZ-VALLE R, VIGIL C, GARCÍA-EULATE R, ZUBIETA JL et al. Neuroimagen en tumores cerebrales. Rev Esp Med Nucl 2011; 30: 47-65.
https://doi.org/10.1016/j.remn.2010.11.001
68. BAGADIA A, PURANDARE H, MISRA BK, GUPTA S. Application of magnetic resonance tractography in the perioperative planning of patients with eloquent region intra-axial brain lesions. J Clin Neurosci 2011; 18: 633-639.
https://doi.org/10.1016/j.jocn.2010.08.026
69. BERNTSEN EM, GULATI S, SOLHEIM O, KVISTAD KA, TORP SH, SELBEKK T et al. Functional magnetic resonance imaging and diffusion tensor tractography incorporated into an intraoperative 3-dimensional ultrasound-based neuronavigation system: impact on therapeutic strategies, extent of resection, and clinical outcome. Neurosurgery 2010; 67: 251-264.
https://doi.org/10.1227/01.NEU.0000371731.20246.AC
70. KUHNT D, BAUER MHA, BECKER A, MERHOF D, ZOLAL A, RICHTER M et al. Intraoperative visualization of fiber tracking based reconstruction of language pathways in glioma surgery. Neurosurgery 2012; 70: 911-919; discussion 919-920.
https://doi.org/10.1227/NEU.0b013e318237a807
71. MAJCHRZAK K, BOBEK-BILLEWICZ B, TYMOWSKI M, ADAMCZYK P, MAJCHRZAK H, LADZIŃSKI P. Surgical treatment of insular tumours with tractography, functional magnetic resonance imaging, transcranial electrical stimulation and direct subcortical stimulation support. Neurol Neurochir Pol 2011; 45: 351-362.
https://doi.org/10.1016/S0028-3843(14)60106-7
72. PRABHU SS, GASCO J, TUMMALA S, WEINBERG JS, RAO G. Intraoperative magnetic resonance imaging-guided tractography with integrated monopolar subcortical functional mapping for resection of brain tumors. Clinical article. J Neurosurg 2011; 114: 719-726.
https://doi.org/10.3171/2010.9.JNS10481
73. ZHAO Y, CHEN X, WANG F, SUN G, WANG Y, SONG Z et al. Integration of diffusion tensor-based arcuate fasciculus fibre navigation and intraoperative MRI into glioma surgery. J Clin Neurosci 2012; 19: 255-261.
https://doi.org/10.1016/j.jocn.2011.03.041
74. ZHAO Y, CHEN X-L, WANG F, SUN G-C, WANG Y-B, SONG Z-J et al. [Application of diffusion tensor imaging-based arcuate fasciculus tractography and intraoperative arcuate fasciculus navigation]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2011; 33: 499-503.
75. KRIEG SM, RINGEL F, MEYER B. Functional guidance in intracranial tumor surgery. Per Med 2012; 1: 59-64.
https://doi.org/10.1016/j.permed.2012.03.014
76. ABE T, BLACK PM, OJEMANN RG, HEDLEY-WHITE ET. Cerebral edema in intracranial meningiomas: evidence for local and diffuse patterns and factors associated with its occurrence. Surg Neurol 1994; 42: 471-475.
https://doi.org/10.1016/0090-3019(94)90075-2
77. HASSO AN, BELL SA, TADMOR R. Intracranial vascular tumors. Neuroimaging Clin N Am 1994; 4: 849-870.
https://doi.org/10.1016/S1052-5149(25)00262-X
78. PAPADOPOULOS MC, SAADOUN S, BINDER DK, MANLEY GT, KRISHNA S, VERKMAN AS. Molecular mechanisms of brain tumor edema. Neuroscience 2004; 129: 1011-1020.
https://doi.org/10.1016/j.neuroscience.2004.05.044
79. HARDWIDGE C, HETTIGE S. Tumours of the central nervous system. Surgery (Oxford) 2012; 30: 7.
https://doi.org/10.1016/j.mpsur.2011.12.008
80. VAN BREEMEN MSM, WILMS EB, VECHT CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6: 421-430.
https://doi.org/10.1016/S1474-4422(07)70103-5
81. LOTE K, STENWIG AE, SKULLERUD K, HIRSCHBERG H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998; 34: 98-102.
https://doi.org/10.1016/S0959-8049(97)00374-2
82. VECHT CJ, WAGNER GL, WILMS EB. Treating seizures in patients with brain tumors: Drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003; 30: 49-52.
https://doi.org/10.1053/j.seminoncol.2003.11.030
83. VECHT CJ, VAN BREEMEN M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006; 67: S10-13.
https://doi.org/10.1212/WNL.67.12_suppl_4.S10
84. BOARINI DJ, BECK DW, VANGILDER JC. Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery 1985;16:290-2.
https://doi.org/10.1227/00006123-198503000-00002
85. COHEN N, STRAUSS G, LEW R, SILVER D, RECHT L. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988; 6: 1621-1624.
https://doi.org/10.1200/JCO.1988.6.10.1621
86. MAHALEY MS, DUDKA L. The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg Neurol 1981; 16: 399-401.
https://doi.org/10.1016/0090-3019(81)90227-5
87. DE SANTIS A, VILLANI R, SINISI M, STOCCHETTI N, PERUCCA E. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 2002; 43: 175-182.
https://doi.org/10.1046/j.1528-1157.2002.24801.x
88. PATSALOS PN, FRÖSCHER W, PISANI F, VAN RIJN CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-385.
https://doi.org/10.1046/j.1528-1157.2002.13001.x
89. FLEMING AJ, CHI SN. Brain tumors in children. Curr Probl Pediatr Adolesc Health Care 2012; 42: 80-103.
https://doi.org/10.1016/j.cppeds.2011.12.002
90. LYNAM LM, LYONS MK, DRAZKOWSKI JF, SIRVEN JI, NOE KH, ZIMMERMAN RS et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 2007; 109: 634-638.
https://doi.org/10.1016/j.clineuro.2007.05.017
91. WOLF HK, ROOS D, BLÜMCKE I, PIETSCH T, WIESTLER OD. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol 1996; 91: 376-384.
https://doi.org/10.1007/s004010050439
92. KAHLENBERG CA, FADUL CE, ROBERTS DW, THADANI VM, BUJARSKI KA, SCOTT RC et al. Seizure prognosis of patients with low-grade tumors. Seizure 2012;21:540-5.
https://doi.org/10.1016/j.seizure.2012.05.014
93. TREMONT-LUKATS IW, RATILAL BO, ARMSTRONG T, GILBERT MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008: CD004424.
https://doi.org/10.1002/14651858.CD004424.pub2
94. KERRIGAN S, GRANT R. Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst Rev 2011: CD008586.
https://doi.org/10.1002/14651858.CD008586
95. LIM DA, TARAPORE P, CHANG E, BURT M, CHAKALIAN L, BARBARO N et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol 2009; 93: 349-354.
https://doi.org/10.1007/s11060-008-9781-4
96. WU AS, TRINH VT, SUKI D, GRAHAM S, FORMAN A, WEINBERG JS et al. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg 2013.
https://doi.org/10.3171/2012.12.JNS111970
97. KOMOTAR RJ, RAPER DMS, STARKE RM, IORGULESCU JB, GUTIN PH. Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy. J Neurosurg 2011; 115: 483-490.
https://doi.org/10.3171/2011.4.JNS101585
98. HARDESTY DA, SANBORN MR, PARKER WE, STORM PB. Perioperative seizure incidence and risk factors in 223 pediatric brain tumor patients without prior seizures. J Neurosurg Pediatr 2011; 7: 609-615.
https://doi.org/10.3171/2011.3.PEDS1120
99. TROUSSEAU A. Phlegmasia alba dolens. Clin Med Hotel Dieu De Paris 1865; 3: 94-96.
100. HEIT JA, SILVERSTEIN MD, MOHR DN, PETTERSON TM, O'FALLON WM, MELTON LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815.
https://doi.org/10.1001/archinte.160.6.809
101. SILVERSTEIN MD, HEIT JA, MOHR DN, PETTERSON TM, O'FALLON WM, MELTON LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
https://doi.org/10.1001/archinte.158.6.585
102. PREUSSER M, DE RIBAUPIERRE S, WÖHRER A, ERRIDGE SC, HEGI M, WELLER M et al. Current concepts and management of glioblastoma. Ann Neurol 2011; 70: 9-21.
https://doi.org/10.1002/ana.22425
103. BRANDES AA, SCELZI E, SALMISTRARO G, ERMANI M, CAROLLO C, BERTI F et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 1997; 33: 1592-1596.
https://doi.org/10.1016/S0959-8049(97)00167-6
104. SJÖBLOM L, HÅRDEMARK HG, LINDGREN A, NORRVING B, FAHLÉN M, SAMUELSSON M et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001; 32: 2567-2574.
https://doi.org/10.1161/hs1101.098523
105. HYLEK EM, SINGER DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
https://doi.org/10.7326/0003-4819-120-11-199406010-00001
106. PERRY JR. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents. Curr Opin Neurol 2010; 23: 592-596.
https://doi.org/10.1097/WCO.0b013e32833feb73
107. LEE AYY. Epidemiology and management of venous thromboembolism in patients with cancer. Thrombosis Research 2003; 110: 167-172.
https://doi.org/10.1016/S0049-3848(03)00347-5
108. HORSTED F, WEST J, GRAINGE MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 9: e1001275.
https://doi.org/10.1371/journal.pmed.1001275
109. COLLEN JF, JACKSON JL, SHORR AF, MOORES LK. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest 2008; 134: 237-249.
https://doi.org/10.1378/chest.08-0023
110. GEERTS WH, BERGQVIST D, PINEO GF, HEIT JA, SAMAMA CM, LASSEN MR ET AL. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
https://doi.org/10.1378/chest.08-0656
111. MUNTZ JE, MICHOTA FA. Prevention and management of venous thromboembolism in the surgical patient: options by surgery type and individual patient risk factors. Am J Surg 2010; 199: S11-20.
https://doi.org/10.1016/j.amjsurg.2009.10.007
112. TEN CATE-HOEK AJ, PRINS MH. Low molecular weight heparins in cancer: Management and prevention of venous thromboembolism in patients with malignancies. Thromb Res 2008; 122: 584-598.
https://doi.org/10.1016/j.thromres.2006.12.026
113. IMBERTI D, DI NISIO M, DONATI MB, FALANGA A, GHIRARDUZZI A, GUARNERI D et al. Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2009; 124: e32-e40.
https://doi.org/10.1016/j.thromres.2009.08.006
114. KHEMASUWAN D, DIVIETRO ML, TANGDHANAKANOND K, POMERANTZ SC, EIGER G. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010; 123: 60-65.
https://doi.org/10.1016/j.amjmed.2009.05.025
115. LYMAN GH, KHORANA AA, FALANGA A, CLARKE-PEARSON D, FLOWERS C, JAHANZEB M et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
https://doi.org/10.1200/JCO.2007.14.1283
116. LUKINS MB, MANNINEN PH. Hyperglycemia in patients administered dexamethasone for craniotomy. Anesth Analg 2005; 100: 1129-1133.
https://doi.org/10.1213/01.ANE.0000146943.45445.55
117. HANS P, VANTHUYNE A, DEWANDRE PY, BRICHANT JF, BONHOMME V. Blood glucose concentration profile after 10 mg dexamethasone in non-diabetic and type 2 diabetic patients undergoing abdominal surgery. Br J Anaesth 2006; 97: 164-170.
https://doi.org/10.1093/bja/ael111
118. MCGIRT MJ, CHAICHANA KL, GATHINJI M, ATTENELLO F, THAN K, RUIZ AJ et al. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 2008; 63: 286-291; discussion 291.
https://doi.org/10.1227/01.NEU.0000315282.61035.48
119. DERR RL, YE X, ISLAS MU, DESIDERI S, SAUDEK CD, GROSSMAN SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 2009; 27: 1082-1086.
https://doi.org/10.1200/JCO.2008.19.1098
120. SEYFRIED TN, SANDERSON TM, EL-ABBADI MM, MCGOWAN R, MUKHERJEE P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 2003; 89: 1375-1382.
https://doi.org/10.1038/sj.bjc.6601269
121. SEYFRIED TN, MUKHERJEE P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab (Lond) 2005; 2: 30.
https://doi.org/10.1186/1743-7075-2-30
122. PECA C, PACELLI R, ELEFANTE A, DEL BASSO DE CARO ML, VERGARA P, MARINIELLO G et al. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin Neurol Neurosurg 2009; 111: 331-334.
https://doi.org/10.1016/j.clineuro.2008.11.003
123. DI CHIRO G, OLDFIELD E, WRIGHT DC, DE MICHELE D, KATZ DA, PATRONAS NJ et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988; 150: 189-197.
https://doi.org/10.2214/ajr.150.1.189
124. LEE WH, SONNTAG WE, MITSCHELEN M, YAN H, LEE YW. Irradiation induces regionally specific alterations in pro-inflammatory environments in rat brain. Int J Radiat Biol 2010; 86: 132-144.
https://doi.org/10.3109/09553000903419346
125. TAKANO T, LIN JH, ARCUINO G, GAO Q, YANG J, NEDERGAARD M. Glutamate release promotes growth of malignant gliomas. Nat Med 2001; 7: 1010-1015.
https://doi.org/10.1038/nm0901-1010
126. HAWKINS RA, MOKASHI A, DEJOSEPH MR, VIÑA JR, FERNSTROM JD. Glutamate permeability at the blood-brain barrier in insulinopenic and insulin-resistant rats. Metabolism 2010; 59: 258-266.
https://doi.org/10.1016/j.metabol.2009.07.022
127. YANG C, SUDDERTH J, DANG T, BACHOO RM, BACHOO RG, MCDONALD JG et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009; 69: 7986-7993.
https://doi.org/10.1158/0008-5472.CAN-09-2266
128. DEBERARDINIS RJ, MANCUSO A, DAIKHIN E, NISSIM I, YUDKOFF M, WEHRLI S ET AL. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007; 104: 19345-19350.
https://doi.org/10.1073/pnas.0709747104
129. NEWSHOLME P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr 2001; 131: 2515S-2522S; discussion 2523S-2524S.
https://doi.org/10.1093/jn/131.9.2515S
130. DEBERARDINIS RJ, CHENG T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010; 29: 313-324.
https://doi.org/10.1038/onc.2009.358
131. GREENE AE, TODOROVA MT, SEYFRIED TN. Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. J Neurochem 2003; 86: 529-537.
https://doi.org/10.1046/j.1471-4159.2003.01862.x
132. WEINDRUCH R. The retardation of aging by caloric restriction: studies in rodents and primates. Toxicol Pathol 1996; 24: 742-745.
https://doi.org/10.1177/019262339602400618
133. BIRT DF, YAKTINE A, DUYSEN E. Glucocorticoid mediation of dietary energy restriction inhibition of mouse skin carcinogenesis. J Nutr 1999; 129: 571S-574S.
https://doi.org/10.1093/jn/129.2.571S
134. DUAN W, LEE J, GUO Z, MATTSON MP. Dietary restriction stimulates BDNF production in the brain and thereby protects neurons against excitotoxic injury. J Mol Neurosci 2001; 16: 1-12.
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
